Neurokinin-1 receptor is highly expressed in cervical cancer and its antagonist induces cervical cancer cell apoptosis

Eur J Histochem. 2023 Jan 11;67(1):3570. doi: 10.4081/ejh.2023.3570.

Abstract

Neurokinin-1 receptor (NK1R) belongs to tachykinin receptor family. Recent studies have suggested that NK1R was upregulated in cancer tissues including breast cancer, glioma and melanoma. Furthermore, NK1R antagonists have been employed to exert anti-tumor effect and promote cancer cell apoptosis. However, the role of NK1R in cervical cancer remains largely unknown. In this study, we aimed to detect the expression of NK1R in cervical cancer and evaluate the anti-tumor effects of NK1R antagonist on cervical cancer cells. We found that NK1R was highly expressed in cervical cancer tissues than in adjacent normal cervical tissues. Furthermore, by using NK1R antagonist we demonstrated that NK1R antagonist inhibited the viability and induced the apoptosis of cervical cancer cells in a dose-dependent manner, and the mechanism may be related to the inhibition of ERK activation and the regulation of apoptosis proteins Bcl-2 and BAX. In conclusion, these findings suggest that NK1R plays an oncogenic role in cervical cancer and is a promising target for cervical cancer therapy.

MeSH terms

  • Apoptosis
  • Cell Line, Tumor
  • Female
  • Humans
  • Neurokinin-1 Receptor Antagonists* / pharmacology
  • Receptors, Neurokinin-1* / metabolism
  • Uterine Cervical Neoplasms* / drug therapy

Substances

  • Neurokinin-1 Receptor Antagonists
  • Receptors, Neurokinin-1

Grants and funding

Funding: This study was supported by Hebei Province Medical Science Research Key Project Program (no. 20150337).